Eisai announces agreement to set up new gastrointestinal speciality company

pharmafile | March 30, 2016 | News story | Manufacturing and Production, Research and Development, Sales and Marketing Ajinomoto, Eisai, absorption, acquisition, ea pharma, gastrointestinal, merger, speciality 

Eisai (TYO: 4523) and Ajinomoto Co. (TYO: 2802) have announced an agreement to establish a new gastrointestinal speciality pharmaceutical company, EA Pharma.

Effective from 1st April 2016, EA Pharma will be formed through the splitting off of a portion of Eisai’s gastrointestinal disease treatment business and its subsequent succession by Ajinomoto Pharmaceuticals via an absorption-type split.

Eisai’s 60 years of innovation within this disease area will be integrated with Ajinomoto’s amino acids expertise to form a gastrointestinal speciality pharma with a full value chain including research and development, production and logistics, and sales and marketing.

EA Pharma has set out its corporate vision, which is to specialise in the likes of inflammatory bowel disease (IBD), as well as striving to address unmet needs through research and development in this disease area. The company will be based in Tokyo, have approximately 1,250 employees and be headed by president and CEO, Hajime Shimizu.

Sean Murray

Related Content

Syncona to acquire Freeline Therapeutics for $28.3m

Freeline Therapeutics has announced that it has entered into a definitive agreement with newly established …

Merck to acquire Caraway Therapeutics for up to $610m

Merck (known as MSD outside of the US and Canada) and Caraway Therapeutics have announced …

Astellas Pharma to acquire Propella Therapeutics for $175m

Astellas Pharma and Propella Therapeutics have announced that Astellas and Propella have entered a merger …

Latest content